4 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 4 of 4 clinical reviews.
Evidence-based guide to alirocumab (Praluent) for ASCVD secondary prevention, including dosing protocols, ODYSSEY OUTCOMES trial data, and clinical guidelines for PCSK9 inhibitor use.
A clinical review of alirocumab (Praluent) used off-label for ASCVD secondary prevention, including ODYSSEY OUTCOMES trial data, risk-benefit analysis, FDA-approved indications, and practical prescribing guidance.
Evidence-based monitoring protocol for alirocumab (Praluent) in familial hypercholesterolemia (FH), including lipid panel timing, safety labs, injection-site surveillance, and when to adjust therapy.
A clinical guide to alirocumab (Praluent) for familial hypercholesterolemia, covering the FDA-approved indication, off-label use in homozygous FH, evidence quality, dosing, risks, and how it compares to evolocumab.